| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Enrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without concomitant thyroid eye disease); Phase 2a topline results expected in the se... |
| 14 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
Introductory. Yarrow Bioscience, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,769,231 shares of its common stock, par valu... |
| 10 Sep 2026 |
8-K: Other Events
Yarrow Bioscience, Inc. (“Yarrow”) is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Yarrow’s lead product candidate, YB-101 (also known as GenSci098), is a humanize... |
| 30 Jul 2026 |
8-K: Other Events
On July 29, 2026, Yarrow Bioscience, Inc. (the “Company”) entered into an exchange agreement with a certain existing stockholder (the “Stockholder”), pursuant to which the Stockholder agreed to exchange an aggregate of 133,290 shares of ... |
| 28 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +8 more
Section 1.1 Registered Office. The registered office of Yarrow Bioscience, Inc., a Delaware corporation (the “Corporation”), shall be fixed in the Amended and Restated Certificate of Incorporation of the Corporation (as the same may be a... |
| 21 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience |
| 20 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders
In connection with the Merger, VYNE held a special meeting in lieu of the annual meeting of VYNE stockholders on July 16, 2026 (the “Special Meeting”), at which the Company’s stockholders voted on the proposals set forth below relating t... |
| 14 Jul 2026 |
8-K: Regulation FD Disclosure
2 Disclaimers The information contained in this presentation has been prepared by Yarrow Bioscience, Inc. and its affiliates (“Yarrow” or t he “Company”) and contains information pertaining to the business and operations of the Company. ... |
| 10 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share |
| 21 May 2026 |
8-K: Regulation FD Disclosure
1 Bringing life into balance Yarrow Bioscience Overview May 2026 |
| 11 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed in a Current Report on Form 8-K filed by VYNE Therapeutics Inc. (the “Company”) on September 12, 2025, the Company received a notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that the Company is not in co... |
| 30 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
This Amendment No. 1 to Agreement and Plan of Merger and reorganization (this “Amendment”) is made as of January 30, 2026, with respect to that certain Agreement and Plan of Merger and Reorganization (as amended to date, the “Merger Agre... |
| 17 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more
Certificate of Merger, including certificate of incorporation of the Surviving Corporation attached as Exhibit A thereto, incorporated by reference into this Agreement |
| 12 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On December 12, 2025, VYNE Therapeutics Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s def... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
BRIDGEWATER, N.J., November 6, 2025 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated c... |
| 12 Sep 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On September 11, 2025, VYNE Therapeutics Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 p... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Implemented cost reductions extend cash runway into first half of 2027 |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
BRIDGEWATER, N.J., May 8, 2025 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediate... |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
BRIDGEWATER, N.J., March 6, 2025 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-media... |
Loading...